The Society for Vascular Surgery considers the placement and maintenance of arteriovenous hemodialysis access to be an important component of any vascular surgery practice. Therefore, the Society has long been involved in setting the standards for the management of arteriovenous access. Formulating clinical recommendations in this area is the latest effort by the Society to improve the management of arteriovenous access on a national level. To provide an unbiased study of the evidence and to help in formulating the recommendations, the Society used the Knowledge and Encounter Research (KER) Unit of the Mayo Clinic College of Medicine, Rochester, Minn, to review the available evidence and advise a multidisciplinary group of access surgeons and nephrologists in formulating the clinical recommendations. To review the evidence, randomized and observational study designs were both considered. Whenever possible, systematic reviews and meta-analyses of the literature were used because, compared with individual studies, they generate more precise estimates of treatment effects and their results are applicable to a wider range of patients. On behalf of the Society, the group issued its recommendations following the Grading of Recommendations Assessment, Development and Evaluation (GRADE) format; this format disentangles the strength of recommendations from the quality of the evidence and encourages statements about the underlying values and preferences relevant to the particular recommendation. The recommendations are classified as strong (denoted by the phrase "we recommend") or weak (denoted by the phrase "we suggest"); and the quality of evidence is classified as high, moderate, low, or very low. These recommendations are not meant to supersede clinical judgment; rather, they should be used as a guide for the practicing surgeon and nephrologist as the decision is being made for the placement and subsequent procedures and management of arteriovenous hemodialysis access are being considered. ( J Vasc Surg 2008;48:26S-30S.)
The Society for Vascular Surgery undertook the task of developing evidence-based guidelines to assist patients and clinicians in the process of decision making. To provide better understanding of these guidelines and facilitate their integration into daily practice, we present the methodologic framework that guideline developers have used to formulate their recommendations. In this supplement, practice guidelines for arteriovenous hemodialysis access and the study of the evidence available in this field are included. In this article, we discuss the evaluation and synthesis of research evidence and the formulation of clear and helpful clinical practice recommendations using the vascular access reviews as examples.
USING RESEARCH EVIDENCE TO FORMULATE RECOMMENDATIONS
Randomized controlled trials (RCTs) are the only study design known to balance known and unknown prognostic risk factors between study arms. Hence, RCTs are considered the gold standard study design to evaluate the effectiveness of therapeutic and diagnostic interventions. However, not all randomized trials offer similarly strong inferences because trialists may or may not use the various measures intended to reduce the risk of bias, such as allocation concealment, blinding, and the intention-to-treat principle. For instance, when the Society for Vascular Surgery evaluated the efficacy of vascular access surveillance, only three of the 10 relevant RCTs protected randomization by assuring that the person assigning patients to a study arm was unaware of the randomization sequence, a procedure called allocation concealment. This procedure usually requires the use of central randomization (eg, the investigator called a central location with patient characteristics and received the arm allocation) or the use of sealed, numbered, and opaque envelopes. 1 Patients and surgeons were appropriately not blinded in these trials; however, data collectors and researchers ascertaining the outcomes could have been blinded to reduce bias; the former was done in five of 10 RCTs and the latter was done in only one RCT.
In the comparison between autogenous and prosthetic accesses, it was unclear whether trials did not report or did not adhere to the intention-to-treat principle, by which researchers set up procedures and resources to keep randomized participants in the arm to which they were ran- ; Division of Endocrinology, Mayo Clinic, Rochester c domized, with no crossover to the other arm. Hence, the inferences from these trials need to be interpreted in the context of the described methodologic limitations.
Moreover, the evaluation of surgical interventions presents challenges to the use of the randomized trials. Patients are reluctant to be randomized to procedures that may be associated with permanent consequences or scars, blinding surgeons and sham surgeries are often unfeasible, and the duration of required follow-up may be too long and impractical for RCTs. 2 As a consequence, evidence-based surgeons have relied extensively on observational studies to this point: only 3.4% of all publications in the leading surgical journals are RCTs, and more than half of these RCTs compared medical therapies in surgical patients rather than alternative surgical procedures or surgical vs medical or radiologic interventions. 3 Recent innovations in the design of surgical trials may overcome some of the limitations of traditional RCTs in surgery, provide the bias protection that randomization offers, and gain the ability to make strong inferences about the efficacy of surgical interventions. An example of these innovations is the expertise-based RCT. Whereas participants in conventional RCTs are randomized to one of two interventions (A or B) and individual clinicians give intervention A to some participants and B to others, participants in expertise-based RCTs are randomized to clinicians with expertise in intervention A or clinicians with expertise in intervention B and the clinicians perform only the procedure they are expert in. 4 Trials of carotid endarterectomy performed by vascular surgeons vs stenting performed by interventional radiologists are examples of expertise-based RCTs.
Observational studies are unlikely to provide the same degree of protection against bias in ascertainment of the efficacy of interventions compared with high-quality randomized trials. Their quality can be improved, however, when investigators include measures aimed at reducing bias. Some of these measures (parallel to those that enhance the quality of randomized trials) include selecting adequate populations, making them appropriately comparable by means of matching or statistical adjustment by key predictors of outcome, ensuring adequate ascertainment of the exposures and outcomes at baseline, planning long enough follow-up to allow time for critical outcomes to develop, and blinding the assessment of outcomes in both groups. 5, 6 Hence, in developing clinical practice guidelines for the Society for Vascular Surgery, we considered evidence generated by both study designs: RCTs and observational studies that included concurrent comparison cohorts. In addition, it is important to recognize the inherent limitations of both designs when applied to surgical interventions in that surgical outcomes are often influenced by other factors such as the surgeons' learning curve and experience, surgical volume, institution characteristics, and the quality of perioperative care. 4 These factors are difficult to assess and are often not reported in the published literature.
THE ROLE OF EVIDENCE SYNTHESIS IN FORMULATING HIGH QUALITY PRACTICE GUIDELINES
The ideal evidence-based recommendation should consider all pertinent evidence. However, with Ͼ1800 new citations indexed in MEDLINE each day and Ͼ16 million citations accrued to date, 7 it is unrealistic to expect that one or a few experts would be aware of the totality of evidence about a particular subject. Furthermore, if experts choose the evidence they bring to bear in formulating recommendations without explicit and reproducible criteria, they run the risk of reviewing an incomplete and biased sample of the available research. Thus, in pursuit of finding the best evidence for guideline development, a rigorous systematic review of the literature is paramount. In contrast to traditional literature reviews, which are nonexhaustive, unsystematic, and can be biased, systematic reviews address a focused clinical question using methods designed to reduce the likelihood of bias in the identification, selection, critical appraisal, description, and summary of the totality of the relevant literature. Compared with the primary studies they seek to summarize, systematic reviews offer greater precision in estimating treatment effects, particularly when these reviews include well-conducted quantitative summary of the results (ie, meta-analysis) and provide results that are applicable to a wider range of patients. 8 The process of conducting systematic reviews starts by defining the clinical question in terms of the population, intervention, comparison, and outcomes. Librarians with expertise in systematic reviews conduct a sensitive-but not very specific-search of relevant bibliographic databases. Reviewers, working independently and in pairs, appraise studies with predetermined criteria for inclusion and exclusion, assess the quality of studies, and abstract relevant data. Results are summarized qualitatively or quantitatively. To ensure high-quality reviews, we monitor and report the agreement among reviewers by using agreement statistics (eg, statistic), contact the authors of primary studies to ensure correct representation of their results and to ask for missing data, explore heterogeneity in the results by conducting subgroup and sensitivity analyses, and assess the potential impact of publication bias on review results (Table I) .
FROM EVIDENCE TO PRACTICE: FORMULATING CLINICAL RECOMMENDATIONS
In using evidence to formulate recommendations, it is helpful for the user of such recommendations to understand how valid, precise, and applicable is the available body of evidence supporting a recommendation (ie, the quality of the evidence). High-quality evidence (ie, estimates of effect for safety and efficacy that are unlikely to change substantially as new research accumulates) provides greater confidence in formulating recommendations. Similarly, it is helpful for the user of practice guidelines to note whether a JOURNAL OF VASCULAR SURGERY Volume 48, Number 5S recommendation is strong (ie, "must do," "must not do") or weak (ie, "may do," "may not do").
Multiple systems have been used to rate the quality of evidence and grade the strength of clinical recommendations. Thankfully for clinicians and other decision makers, there is an emerging consensus among professional organizations toward using one system, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system, for this purpose. 9, 10 The GRADE system classifies recommendations as strong (grade 1) or weak (grade 2) and the quality of the evidence (ie, risk of bias) into one of four categories (high, moderate, low, or very low). To further enhance the interpretation and clarity of the recommendations, guideline developers use the terms "we recommend" to denote strong recommendations, and the less definitive wording "we suggest" to denote weak recommendations.
When guideline developers are confident that the desirable effects of adherence to a recommendation outweigh the undesirable effects, they will make a strong recommendation within the context of a described intervention. Typically, this requires high-or moderate-quality evidence on patient-important outcomes, but on occasion, a strong recommendation can be based on lower-quality evidence. This may occur when the values and preferences that guideline developers bring to bear are such that when considering even low-quality evidence, they are confident that the desirable effects of adherence to a recommendation outweigh the undesirable effects.
A weak recommendation is one for which a guideline panel concludes that the desirable effects of adherence to a recommendation probably outweigh the undesirable effects, but the panel is not confident. Thus, if guideline developers believe that benefits and downsides are finely balanced, or appreciable uncertainty exists about this balance, they offer a weak recommendation. Overall, low-or very low-quality evidence usually leads to weak recommendations because of uncertainty about the balance between risks and benefits. Guideline panels may offer weak recommendations even when high-quality evidence is available because that evidence clearly demonstrates that the benefits and risks are closely balanced.
As described above, study design and conduct are important determinants of the quality of evidence (Table  II) . 11 RCTs allow decision makers to draw causal inferences linking interventions and outcomes with protection against bias. Therefore, RCTs begin with a "high" quality rating, whereas observational studies start with a "low" quality rating. This rating can be downgraded when:
(1) RCTs have serious methodologic limitations; for example, lack of allocation concealment and blinding, or large loss to follow-up; (2) results were inconsistent among trials, (3) trials were indirectly relevant; that is, did not directly apply to the patients, interventions, or outcomes of interest; (4) results were imprecise due to small number of studies and events, or (5) reporting bias might have affected the estimates (usually overestimated the beneficial effect or the harmful effect of treatment).
For example, when evaluating the effectiveness of access surveillance on the survival of the vascular access of hemodialysis we note that (1) there was important inconsistency between study results, with 60% of the observed variability being attributed to true differences in the results across trials rather than to chance, (2) some RCTs reported only on the effect of the interventions on access thrombosis, which is a surrogate of the more important outcome, access loss or abandonment, and (3) only six of 12 studies evaluated access failure with a total of only 94 events (ie, accesses lost) in the surveillance group vs 88 events in the no surveillance group, which produced a wide confidence interval. Therefore, the overall clinical trial evidence was downgraded due to inconsistency, indirectness and imprecision, respectively; that is, from high-quality evidence to very low-quality evidence. 1 On the other hand, the quality of evidence of observational studies can be upgraded if (1) a very large treatment effect was observed, (2) all plausible confounders would reduce the magnitude of the treatment effect, yet the effect remains sizable, and (3) a dose-response gradient was noted. An example of evidence that was upgraded comes from the comparison of autogenous access with prosthetic access for hemodialysis. We noted that placing an autogenous access produced a large effect in decreasing the risk of access infection (relative risk, 0.22; or five times reduction of risk), which led to upgrading the quality of the evidence. 12 Finally, the GRADE system offers insights into the role of values and preferences when it disentangles the strength of recommendations from the quality of the evidence and when it encourages statements about the underlying values and preferences relevant to the recommendations. For example, the vascular access committee issued a strong recommendation for using distal arm autogenous access as a a Exceptionally strong evidence from unbiased observational studies includes (1) evidence from studies that yield estimates of the treatment effect that are large and consistent and (2) evidence where all potential biases may be working to underestimate an apparent treatment effect, and therefore, the actual treatment effect is likely to be larger than that suggested by the study data, and (3) evidence where a dose-response gradient exists.
first-line access despite very low-quality evidence. The evidence for this recommendation was considered to have very low quality because most of the studies were nonrandomized (80 of 83), the study cohorts were prognostically imbalanced at baseline, outcome assessors were mostly unblinded, apparent reporting bias was present, and results were inconsistent among studies to the extent that the proportion of heterogeneity that is not attributable to chance in most outcomes Ͼ50% and often Ͼ90%. These limitations in the quality of evidence notwithstanding, the committee issued a strong recommendation because they placed higher value on optimizing patientimportant outcomes such as preventing death, access infection, local complications, and achieving a longer period of time with successful dialysis; all were features thought to be more associated with the autogenous access. In recommending distal upper extremity access sites despite the very low quality evidence, they also placed high value on the preservation of proximal veins or future access placement. The committee placed lower value on some of the characteristics of the prosthetic access such as higher reimbursement for placement, ready off-the-shelf availability, and shorter time to first use for dialysis. Hence, the guideline authors made a strong recommendation when they assumed that the pertinent values and preferences across a broad range of informed patients are consistent with the recommended action.
THE FUTURE
The Society for Vascular Surgery belongs to a select but expanding group of professional organizations that has endorsed an approach that is the state-of-the-art in guideline formulation and grading. This position is not without challenges. The GRADE Working Group (www.gradeworkinggroup.org) is identifying the best approaches to the grading of diagnostic recommendations. There is considerable uncertainty on how to incorporate considerations about resource utilization and societal priorities in health care. Also, mechanisms to incorporate patient preferences into guideline formulation are in their infancy.
Other challenges for the Society involve the use of the guidelines to inform policies in support of quality improvement efforts. For example, it is plausible that strongly recommended procedures could lead to process-of-care parameters that can be part of quality assessment and incentive schemes. Weak recommendations, on the other hand, may indicate areas not ready for quality improvement. How the Society, and other organizations, can move from guideline formulation to practice implementation represents yet another frontier in this field.
In future articles, we will keep the vascular surgery community abreast of developments in the methodology of guideline development while we continue to improve on the procedures we have began to use in response to users' feedback.
